Lucitanib

small molecule

Identifier: CI-DRUG-00000350
Entity page: /drug/lucitanib ↗
Edges: 41

Neighbours: 17 cancers5 genes1 variants10 trials
Drawn: 33 of 33 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Lucitanib predicts response to …PREDICTS_RESPONSE_TO2 of 2
← predicts response to	FGFR1 Amplificationamplification	sensitivity	B	Malignant Breast Neoplasm	1	Curated	civic	graph →
← predicts response to	FGFR1 Amplificationamplification	sensitivity	D

Lucitanib targets …TARGETS5 of 5
→ targets	FGFR2	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	FLT4	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	KDR	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	FGFR1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	FLT1	—	INHIBITOR	—	1	Curated	chembl	graph →

Lucitanib targets …TARGETS5 of 5

→ targets

FGFR2

—

INHIBITOR

—

Curated

Lucitanib investigated for …INVESTIGATED_FOR8 of 8
→ investigated for	Malignant Breast Neoplasmcancer_family	supports	B	Malignant Breast Neoplasm	1	Curated	civic	graph →
→ investigated for	Malignant Breast Neoplasmcancer_family	supports	D	Malignant Breast Neoplasm	1	Curated	civic	graph →
→ investigated for	Lung Neoplasmcancer_family	unknown	2	Lung Neoplasm	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	2	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	2	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	2	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Small Cell Carcinomasubtype	unknown	2	Lung Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Female Reproductive System Neoplasmsubtype	unknown	1	Female Reproductive System Neoplasm	1	Curated	chembl	graph →

Lucitanib investigated in trials for …INVESTIGATED_IN_TRIALSderived14 of 14
→ investigated in trials for	Solid Neoplasm 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Small Cell Carcinomasubtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Neoplasmcancer_family 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Female Reproductive System Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Female Reproductive System Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Thymus Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Triple-Negative Breast Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Urothelial Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →

Lucitanib studied in …STUDIED_INderived10 of 12show all (up to 200)
→ studied in	NCT07824505Phase 2 · completed Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy · 12 trials list this drug (0 active)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01283945Phase 1/Phase 2 · completed Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors · 12 trials list this drug (0 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02053636Phase 2 · completed A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer · 12 trials list this drug (0 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03992131Phase 1/Phase 2 · terminated A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) · 12 trials list this drug (0 active)	—	—	Solid Neoplasm,Malignant Ovarian Neoplasm,Urothelial Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT04151563Phase 1/Phase 2 · withdrawn A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy · 12 trials list this drug (0 active)	—	—	Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04042116Phase 1/Phase 2 · suspended A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor · 12 trials list this drug (0 active)	—	—	Solid Neoplasm,Malignant Female Reproductive System Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02202746Phase 2 · terminated A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer · 12 trials list this drug (0 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04254471Phase 2/Phase 3 · unknown This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients · 12 trials list this drug (0 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02109016Phase 2 · terminated A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations · 12 trials list this drug (0 active)	—	—	Lung Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT02747797Phase 2 · withdrawn Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations · 12 trials list this drug (0 active)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths